Nuclea Nabs $3.4M Deal

Xconomy Boston — 

Nuclea Biotechnologies, the Pittsfield, MA-based developer of genomic tests for cancer research, has raised $3.4 million in new equity financing, according to a regulatory filing. The company, which says on its website that it has collaborations with the Dana-Farber Cancer Institute in Boston and the Johns Hopkins School of Medicine in Baltimore, is seeking to discover genomic signatures that could lead to better diagnosis and prognosis for cancer patients. The company said in July it has closed on a $1 million private placement.